Correction: Novel formulations of oral bisphosphonates in the treatment of osteoporosis (vol 34, pg 2625, 2022)

N. Fuggle; N. Al-Daghri; O. Bock; J. Branco; O. Bruyere; E. Casado; E. Cavalier; B. Cortet; M. de Wit; A. Giusti; P. Halbout; N.C. Harvey; M. Hiligsmann; J.M. Kaufman; A. Kurth; S. Maggi; R. Matijevic; S. Minisola; S. Palacios; R.P. Radermecker; F. Thomasius; S. Tuzun; N. Veronese; J.A. Kanis; J.Y. Reginster; R. Rizzoli; C. Cooper

doi:10.1007/s40520-022-02319-1

Correction: Novel formulations of oral bisphosphonates in the treatment of osteoporosis (vol 34, pg 2625, 2022)

N. Fuggle
, N. Al-Daghri
, O. Bock
, J. Branco
, O. Bruyere
, E. Casado
, E. Cavalier
, B. Cortet
, M. de Wit
, A. Giusti
, P. Halbout
, N.C. Harvey
, M. Hiligsmann
, J.M. Kaufman
, A. Kurth
, S. Maggi
, R. Matijevic
, S. Minisola
, S. Palacios
, R.P. Radermecker

F. Thomasius, S. Tuzun, N. Veronese, J.A. Kanis, J.Y. Reginster, R. Rizzoli, C. Cooper^*

^*Corresponding author for this work

Research output: Contribution to journal › Erratum / corrigendum › Academic

Abstract

In the published article, the author would like to update the following lines from Gastrointestinal adverse events were observed in 31% (n = 319) participants and, of these, 85% (n = 271) were upper gastrointestinal. to History of Gastrointestinal symptoms were observed in 31% (n = 319) participants and, of these, 85% (n = 271) were upper gastrointestinal in the published article. The original article has been updated.

Original language	English
Pages (from-to)	1375-1376
Number of pages	2
Journal	Aging Clinical and Experimental Research
Volume	35
Issue number	6
Early online date	1 Jan 2023
DOIs	https://doi.org/10.1007/s40520-022-02319-1
Publication status	Published - Jun 2023

Access to Document

10.1007/s40520-022-02319-1Licence: CC BY

1 (Systematic) Review article

Novel formulations of oral bisphosphonates in the treatment of osteoporosis
Fuggle, N., Al-Daghri, N., Bock, O., Branco, J., Bruyère, O., Casado, E., Cavalier, E., Cortet, B., de Wit, M., Giusti, A., Halbout, P., Harvey, N. C., Hiligsmann, M., Kaufman, J.-M., Kurth, A., Maggi, S., Matijevic, R., Minisola, S., Palacios, S. & Radermecker, R. P. & 7 others, Thomasius, F., Tuzun, S., Veronese, N., Kanis, J. A., Reginster, J.-Y., Rizzoli, R. & Cooper, C., Nov 2022, In: Aging Clinical and Experimental Research. 34, 11, p. 2625-2634 10 p.
Research output: Contribution to journal › (Systematic) Review article › peer-review

Open Access

Cite this

Fuggle, N., Al-Daghri, N., Bock, O., Branco, J., Bruyere, O., Casado, E., Cavalier, E., Cortet, B., de Wit, M., Giusti, A., Halbout, P., Harvey, N. C., Hiligsmann, M., Kaufman, J. M., Kurth, A., Maggi, S., Matijevic, R., Minisola, S., Palacios, S., ... Cooper, C. (2023). Correction: Novel formulations of oral bisphosphonates in the treatment of osteoporosis (vol 34, pg 2625, 2022). Aging Clinical and Experimental Research, 35(6), 1375-1376. https://doi.org/10.1007/s40520-022-02319-1

@article{b463ae4073a94d2695331f64c05f62e1,

title = "Correction: Novel formulations of oral bisphosphonates in the treatment of osteoporosis (vol 34, pg 2625, 2022)",

abstract = "In the published article, the author would like to update the following lines from Gastrointestinal adverse events were observed in 31\% (n = 319) participants and, of these, 85\% (n = 271) were upper gastrointestinal. to History of Gastrointestinal symptoms were observed in 31\% (n = 319) participants and, of these, 85\% (n = 271) were upper gastrointestinal in the published article. The original article has been updated.",

author = "N. Fuggle and N. Al-Daghri and O. Bock and J. Branco and O. Bruyere and E. Casado and E. Cavalier and B. Cortet and \{de Wit\}, M. and A. Giusti and P. Halbout and N.C. Harvey and M. Hiligsmann and J.M. Kaufman and A. Kurth and S. Maggi and R. Matijevic and S. Minisola and S. Palacios and R.P. Radermecker and F. Thomasius and S. Tuzun and N. Veronese and J.A. Kanis and J.Y. Reginster and R. Rizzoli and C. Cooper",

year = "2023",

month = jun,

doi = "10.1007/s40520-022-02319-1",

language = "English",

volume = "35",

pages = "1375--1376",

journal = "Aging Clinical and Experimental Research",

issn = "1594-0667",

publisher = "Springer",

number = "6",

}

Fuggle, N, Al-Daghri, N, Bock, O, Branco, J, Bruyere, O, Casado, E, Cavalier, E, Cortet, B, de Wit, M, Giusti, A, Halbout, P, Harvey, NC, Hiligsmann, M, Kaufman, JM, Kurth, A, Maggi, S, Matijevic, R, Minisola, S, Palacios, S, Radermecker, RP, Thomasius, F, Tuzun, S, Veronese, N, Kanis, JA, Reginster, JY, Rizzoli, R & Cooper, C 2023, 'Correction: Novel formulations of oral bisphosphonates in the treatment of osteoporosis (vol 34, pg 2625, 2022)', Aging Clinical and Experimental Research, vol. 35, no. 6, pp. 1375-1376. https://doi.org/10.1007/s40520-022-02319-1

TY - JOUR

T1 - Correction: Novel formulations of oral bisphosphonates in the treatment of osteoporosis (vol 34, pg 2625, 2022)

AU - Fuggle, N.

AU - Al-Daghri, N.

AU - Bock, O.

AU - Branco, J.

AU - Bruyere, O.

AU - Casado, E.

AU - Cavalier, E.

AU - Cortet, B.

AU - de Wit, M.

AU - Giusti, A.

AU - Halbout, P.

AU - Harvey, N.C.

AU - Hiligsmann, M.

AU - Kaufman, J.M.

AU - Kurth, A.

AU - Maggi, S.

AU - Matijevic, R.

AU - Minisola, S.

AU - Palacios, S.

AU - Radermecker, R.P.

AU - Thomasius, F.

AU - Tuzun, S.

AU - Veronese, N.

AU - Kanis, J.A.

AU - Reginster, J.Y.

AU - Rizzoli, R.

AU - Cooper, C.

PY - 2023/6

Y1 - 2023/6

N2 - In the published article, the author would like to update the following lines from Gastrointestinal adverse events were observed in 31% (n = 319) participants and, of these, 85% (n = 271) were upper gastrointestinal. to History of Gastrointestinal symptoms were observed in 31% (n = 319) participants and, of these, 85% (n = 271) were upper gastrointestinal in the published article. The original article has been updated.

AB - In the published article, the author would like to update the following lines from Gastrointestinal adverse events were observed in 31% (n = 319) participants and, of these, 85% (n = 271) were upper gastrointestinal. to History of Gastrointestinal symptoms were observed in 31% (n = 319) participants and, of these, 85% (n = 271) were upper gastrointestinal in the published article. The original article has been updated.

U2 - 10.1007/s40520-022-02319-1

DO - 10.1007/s40520-022-02319-1

M3 - Erratum / corrigendum

C2 - 36595210

SN - 1594-0667

VL - 35

SP - 1375

EP - 1376

JO - Aging Clinical and Experimental Research

JF - Aging Clinical and Experimental Research

IS - 6

ER -

Correction: Novel formulations of oral bisphosphonates in the treatment of osteoporosis (vol 34, pg 2625, 2022)

Abstract

Access to Document

Fingerprint

Research output

Novel formulations of oral bisphosphonates in the treatment of osteoporosis

Cite this